NCIt definition : A monoclonal antibody targeting the human complement factor C5a, with potential anti-inflammatory
and immunomodulating activities. Upon administration, vilobelimab specifically targets
and binds to C5a. This prevents the binding of C5a to its receptor C5a receptor (C5aR)
and prevents C5a/C5aR-mediated pro-inflammatory signaling, thereby reducing inflammation
and tissue and organ damage. C5a, a factor in the complement cascade, plays important
roles in inflammation and immunity. C5aR is expressed on multiple cell types including
mast cells, phagocytes, bronchial and alveolar epithelial cells, hepatocytes, astrocytes
and vascular endothelial cells.;